Who
Lee Nisley Newcomer
Director
Company insider
Files Form 4 as: Director, Coherus Oncology; Director, Myriad Genetics.
In numbers
- Trades disclosed
- 18
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $157K
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 5 Dec 2019
- Last trade
- 5 Jun 2026
- Last filed
- 9 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 Jun 2026filed 9 Jun 2026 | CHRS Coherus OncologyBiotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | CHRS Coherus Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | CHRS Coherus Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | CHRS Coherus OncologyBiotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 4 Jun 2026filed 5 Jun 2026 | MYGN Myriad GeneticsDiagnostics & Labs | SEC FORM 4 Code A | —59,701 at $0.00 | filing |
| 4 Jun 2026filed 5 Jun 2026 | MYGN Myriad GeneticsDiagnostics & Labs | SEC FORM 4 Code A | —59,701 at $0.00 | filing |
| 12 Jun 2025filed 13 Jun 2025 | CHRS Coherus Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —112,000 at $0.00 | filing |
| 5 Jun 2025filed 6 Jun 2025 | MYGN Myriad GeneticsDiagnostics & Labs | SEC FORM 4 Code A | —49,796 at $0.00 | filing |
| 6 Jun 2024filed 7 Jun 2024 | MYGN Myriad GeneticsDiagnostics & Labs | SEC FORM 4 Code A | —15,695 at $0.00 | filing |
| 3 Jun 2024filed 5 Jun 2024 | CHRS Coherus Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —112,000 at $0.00 | filing |
| 13 May 2024filed 15 May 2024 | MYGN Myriad GeneticsDiagnostics & Labs | SEC FORM 4 Sold | $157K6,200 at $25.30 | filing |
| 7 Jun 2023filed 9 Jun 2023 | CHRS Coherus Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —38,250 at $0.00 | filing |
| 1 Jun 2023filed 2 Jun 2023 | MYGN Myriad GeneticsDiagnostics & Labs | SEC FORM 4 Code A | —15,151 at $0.00 | filing |
| 2 Jun 2022filed 3 Jun 2022 | MYGN Myriad GeneticsDiagnostics & Labs | SEC FORM 4 Code A | —17,275 at $0.00 | filing |
| 2 Feb 2022filed 4 Feb 2022 | CHRS Coherus Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —54,000 at $0.00 | filing |
| 3 Jun 2021filed 4 Jun 2021 | MYGN Myriad GeneticsDiagnostics & Labs | SEC FORM 4 Code A | —12,848 at $0.00 | filing |
| 4 Dec 2020filed 7 Dec 2020 | MYGN Myriad GeneticsDiagnostics & Labs | SEC FORM 4 Code A | —15,889 at $0.00 | filing |
| 5 Dec 2019filed 6 Dec 2019 | MYGN Myriad GeneticsDiagnostics & Labs | SEC FORM 4 Code A | —11,687 at $0.00 | filing |
News
Financial Review: Myriad Genetics (NASDAQ:MYGN) & AnaptysBio (NASDAQ:ANAB)MYGN · tickerreport.com · 20 Oct 2026Molecular Diagnostic Stock Myriad Genetics (NASDAQ: MYGN) Gains on News of Selling Prenatal Health Testing BusinessMYGN · investorideas.com · 20 Oct 2026FinancialContent - Myriad Genetics (MYGN) Stock Trades Up, Here Is WhyMYGN · financialcontent.com · 20 Oct 2026
0 headlines in the last 90 days name Lee Nisley Newcomer; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.